Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian to Participate in the Leerink Partners Global Biopharma Conference
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
Viridian Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Viridian Announces Proposed Underwritten Public Offering of Common Stock
Viridian Announces Pricing of Public Offering of Shares of Common Stock
Viridian to Present Key 2024 Priorities at J.P. Morgan Healthcare Conference
Viridian to Webcast Presentation at the 42nd Annual J.P. Morgan Conference